Month: May 2024

Management to host conference call and webcast at 8:30am ET PITTSBURGH, May 10, 2024 (GLOBE NEWSWIRE) — Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced that it will report its financial results for the first quarter ended March 31, 2024 before the markets open on Wednesday, May 15, 2024. The company will host a corporate update conference call and live audio webcast at 8:30 a.m. ET.Live Conference Call & Webcast:Toll Free:   877-407-3982International:   201-493-6780Conference ID:   13746389Call...

DALLAS, May 10, 2024 (GLOBE NEWSWIRE) — Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its first quarter 2024 financial results and provided a corporate update. Recent Highlights:With successful completion of feasibility studies, preparations are underway with collaborator for a potential investigator-initiated trial (IIT) in non-small cell lung cancer with folate receptor α (FRα)-CoStAR TIL Exploring opportunities to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need Cash runway expected beyond 2026First Quarter 2024 Financial and Operating Results: As of March 31, 2024, Instil had cash, cash equivalents, marketable securities and long-term investments of $161.5 million,...

ORLANDO, Fla., May 10, 2024 (GLOBE NEWSWIRE) — Gencor Industries, Inc. (the “Company” or “Gencor”) (NYSE American LLC: GENC) announced today net revenues increased 33.4% to $40,676,000 for the quarter ended March 31, 2024 compared with $30,501,000 for the quarter ended March 31, 2023. Gross profit margins for the quarter ended March 31, 2024 were 30.3% compared with 29.8% for the quarter ended March 31, 2023 on improved absorption on increased production and favorable price realization. Product engineering and development expenses increased $19,000 to $893,000 for the quarter ended March 31, 2024, as compared to $874,000 for the quarter ended March 31, 2023. Selling, general and administrative (“SG&A”) expenses increased $1,295,000 to $4,357,000 for the quarter ended March 31, 2024, compared to $3,062,000 for the quarter ended...

NEW YORK, May 10, 2024 (GLOBE NEWSWIRE) — AMC Networks Inc. (“AMC Networks” or the “Company”) (NASDAQ: AMCX) today reported financial results for the first quarter ended March 31, 2024. Chief Executive Officer Kristin Dolan said: “In the first quarter, we continued to execute on our strategic priorities, including the ongoing delivery of healthy free cash flow. As new technologies transform the way media is consumed, we continue to produce great content and make it available to viewers whenever and wherever they want to watch. We recently strengthened our balance sheet by completing a series of financing transactions that meaningfully extended our debt maturities. This creates substantial flexibility for us as we continue to leverage our core strengths and reorient our business around the consumer-driven...

MISSISSAUGA, Ontario, May 10, 2024 (GLOBE NEWSWIRE) — Next Hydrogen Solutions Inc. (the “Company” or “Next Hydrogen”) (TSXV:NXH, OTC:NXHSF), a designer and manufacturer of electrolyzers, is pleased to report its financial results for the first quarter ended March 31, 2024. “In 2024, we intend to: (1) demonstrate our system at a customer site, (2) further improve our energy efficiency to exceed US DOE 2026 targets to world class efficiency levels, (3) complete pilot scale testing of our large-scale product line (up to 8MW per module) targeting large scale 100MW+ solutions, and (4) double our growing backlog,” said Raveel Afzaal, President & CEO. “We are progressing well on all of these goals with a fully financed business plan for 2024 and looking forward to a transformative year. We were honored by a visit by our Deputy Prime...

Final results from RMCL-002 Phase 2 trial to be presented in the Late Breaking Clinical Trials session at the European Renal Association (ERA) Congress on May 25, 2024. An investor call to provide a perspective on CKD with Dr. Arnold Silva and Dr. Steven Coca and a recap of the RMCL-002 data is planned for May 28, 2024 On schedule to resume manufacturing and PROACT 1 Phase 3 trial, commence PROACT 2 Phase 3 trial, and readout interim results from the ongoing REGEN-007 Phase 2 trial in mid-2024 Strengthened leadership team with appointment of two key hires across Clinical and Technical Operations Ended the first quarter with $329 million in cash and cash equivalents and marketable securities, supporting operating plans into Q4 2025WINSTON-SALEM, N.C., May 10, 2024 (GLOBE NEWSWIRE) — ProKidney Corp. (Nasdaq: PROK) (“ProKidney”...

– Company to Host Webcast and Conference Call – BRANFORD, Conn., May 10, 2024 (GLOBE NEWSWIRE) — Sachem Capital Corp. (NYSE American: SACH) announced its financial results for the first quarter ended March 31, 2024. The Company will host a conference call on Friday, May 10, 2024 at 8:00 a.m. Eastern Time to discuss its financial and operating results. John Villano, CPA, Sachem Capital’s Chief Executive Officer, stated: “In the first quarter, we continued to navigate through an evolving and challenging macro environment marked by uncertainty regarding inflation, and the Federal Reserve’s future rate policy. We remain disciplined, and while long-term capital remains relatively unavailable to our borrowers, we are focused on maintaining strong liquidity, growing borrower relationships, and protecting our capital. Our diversified...

— Statistically significant week 96 results from the Phase 2b HARMONY study of EFX in patients with pre-cirrhotic MASH reported during the first quarter of 2024 — — Phase 3 SYNCHRONY Histology and SYNCHRONY Real-World studies in patients with pre-cirrhotic MASH (F2-F3) continue to enroll; SYNCHRONY Outcomes study in patients with compensated cirrhosis due to MASH (F4) on track to be initiated in second quarter of 2024 — SOUTH SAN FRANCISCO, Calif., May 10, 2024 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported first quarter financial results for the period ending March 31, 2024 and provided business updates. “We continued to make significant...

Revenues increase by +23.5% to $6.2 million on higher waste volumes+4.8% gross margin expansion from 64.3% to 69.1%Company provides guidance for topline growth between +23% and +53% for 2024SINGAPORE, May 10, 2024 (GLOBE NEWSWIRE) — ESGL Holdings Limited (NASDAQ: ESGL) (“ESGL” or the “Company”), a sustainable waste solutions provider whose mission is to upcycle industrial waste into circular products using innovative technologies and renewable energy, today reported its financial and operating results for the full year 2023. Financial Results Summary In 2023, revenue totaled $6.2 million, an increase of 23.5% compared to $5.0 million in 2022. Revenue was driven by higher waste volumes, driving waste disposal services to increase by $1.6 million, or 71.8% year-over-year, for 2023. The higher waste management revenue was...

-Biologics License Application (BLA) for HAV™ Accepted by FDA- -BLA Granted Priority Review for Vascular Trauma Indication; PDUFA date set for August 10, 2024- -Raised approximately $43 million in net proceeds from public offering of common stock- -Conference call and live webcast at 8:00 a.m. ET today- DURHAM, N.C., May 10, 2024 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced financial results for the first quarter ended March 31, 2024 and highlighted recent accomplishments advancing the investigational Human Acellular Vessel™ (HAV) closer to planned U.S. market launch. “During the first quarter of 2024, we achieved a major milestone with the acceptance by the Food...